Financials in USD. Standardized financial statements.
A compact view of how Zevra Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $106.47M | $23.61M | $27.46M | $10.16M | $28.65M | $13.29M | $12.84M | $0 | $0 | $0 |
| Revenue Growth? | +350.9% | -14.0% | +170.3% | -64.5% | +115.6% | +3.5% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $16.48M | $7.42M | $2.94M | $222,000 | $2.06M | $1.30M | $2.94M | $324,000 | $336,000 | $175,000 |
| Gross Profit? | $89.99M | $16.20M | $24.52M | $9.94M | $26.59M | $11.98M | $9.89M | -$324,000 | -$336,000 | -$175,000 |
| Gross Margin? | +84.5% | +68.6% | +89.3% | +97.8% | +92.8% | +90.2% | +77.1% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $94.22M | $103.20M | $74.12M | $52.50M | $18.86M | $17.59M | $30.23M | $54.27M | $33.37M | $34.47M |
| Operating Income? | -$4.23M | -$87.00M | -$49.60M | -$42.56M | $7.73M | -$5.61M | -$20.34M | -$55.90M | -$33.37M | -$37.48M |
| EBITDA? | $98.71M | -$76.40M | -$43.54M | -$25.53M | -$7.89M | -$5.43M | -$17.73M | -$53.94M | -$33.03M | -$34.30M |
| Income Before Tax | $86.68M | -$90.14M | -$46.05M | -$26.80M | -$8.52M | -$12.79M | -$24.54M | -$56.59M | -$43.43M | -$16.53M |
| Income Tax Expense | $3.45M | $15.37M | $0 | -$33,000 | $34,000 | -$34,000 | -$22,000 | -$126,000 | -$43,000 | -$15,000 |
| Net Income? | $83.23M | -$105.51M | -$46.05M | -$26.77M | -$8.55M | -$12.76M | -$24.52M | -$56.47M | -$43.39M | -$16.52M |
| EPS? | $1.40 | $-2.28 | $-1.30 | $-0.78 | $-2.11 | $-3.21 | $-13.23 | $-50.39 | $-47.37 | $-18.10 |
| Diluted EPS? | $1.35 | $-2.28 | $-1.30 | $-0.78 | $-2.11 | $-3.21 | $-13.23 | $-50.39 | $-47.37 | $-18.10 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality